Compare Celestica Inc (CLS) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celestica Inc vs Quest Diagnostics Inc — how do they compare? Celestica Inc trades at $338.71 (market cap $39.16B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Celestica Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| CLS | DGX | |
|---|---|---|
Market Cap | $39.16B | $26.21B |
Sector | Technology | Health |
52-Week High | $472.40 | $238.50 |
52-Week Low | $181.34 | $173.49 |
Enterprise Value | $39.44B | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLS trades at $339.46, up 7.91% in 24 hours, with a bearish technical signal but strong fundamentals. Recent Q2 2026 EPS of $2.54 beat estimates, and revenue growth is driven by AI infrastructure demand. The company completed a $3 billion equity offering to fund expansion, though this may cause near-term dilution. Support levels are near $309, with resistance at $313.
Outlook is positive due to robust earnings beats and AI-driven growth, but risks include equity dilution and premium valuation. Analyst consensus is bullish with a $466.50 price target, indicating 37% upside. Investors should weigh growth potential against execution risks and market volatility.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
